GoAI
Get started
Nuwellis, Inc. logo

Nuwellis, Inc.

NUWE

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$1.16

+$0.04 · +3.57%

Aug 21, 4:00 PM ET

Pre-market

$1.19

+$0.03 · +2.59%

Aug 24, 5:13 AM ET

NUWE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

29

Weakening

Sentiment

53

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Michael McCormick
Listed since
Feb 16, 2012
Employees
38

Market position

Day range

Current $1.16

52-week range

Current $1.16

Open
$1.125
Previous close
$1.12
Volume
226.05K
0.1× average
Average volume
2.32M
Average daily volume
Market cap
106.95K USD
Beta
0.29
Market reference 1
50-day average
$2.7304
-57.52% below average
200-day average
$45.9551
-97.48% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.01×
P/B (TTM)
-0.1×
P/S (TTM)
0.01×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
69.69%
Operating margin
-140.62%
Net margin
-123.38%

Financial health

Debt / equity
-0.1×

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-29504.05%
11 comparable reports
Latest EPS result
-26.64
Estimate -23.8 · Miss by 11.93%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates69.36-171.25-411.87-652.48Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -9.55, estimate -0.207, surprise -4524.36%, Miss. Q2 2025, reported May 13, 2025: actual -10.14, estimate -6.61, surprise -53.33%, Miss. Q3 2025, reported Aug 14, 2025: actual -21.35, estimate -6.62, surprise -222.70%, Miss. Q4 2025, reported Nov 12, 2025: actual 19.58, estimate -602.7, surprise +103.25%, Beat. Q1 2026, reported Mar 10, 2026: actual -0.525, estimate -0.546, surprise +3.94%, Beat. Q2 2026, reported May 12, 2026: actual -0.732, estimate -0.35, surprise -109.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -26.64, estimate -23.8, surprise -11.93%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -13.65, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.61M2.28M1.95M1.62MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 2.32M USD, estimate 2.46M USD, surprise -5.67%, Miss. Q2 2025, reported May 13, 2025: actual 1.9M USD, estimate 2.5M USD, surprise -23.84%, Miss. Q3 2025, reported Aug 14, 2025: actual 1.73M USD, estimate 2.2M USD, surprise -21.59%, Miss. Q4 2025, reported Nov 12, 2025: actual 2.22M USD, estimate 2.5M USD, surprise -11.32%, Miss. Q1 2026, reported Mar 10, 2026: actual 2.42M USD, estimate 2.31M USD, surprise +4.94%, Beat. Q2 2026, reported May 12, 2026: actual 2.4M USD, estimate 2.09M USD, surprise +14.76%, Beat. Q3 2026, reported Aug 13, 2026: actual 1.97M USD, estimate 2.42M USD, surprise -18.47%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate 2.51M USD, surprise —, Comparison unavailable.

NUWE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NUWE

research.disclaimer